

Please insert the entirety of the attached "Sequence Listing" immediately prior to the claims.

IN THE CLAIMS

Please amend claims 16, 30, 32, 33, 34, 38, and 40 by replacing them with the following amended replacement claims:

16. (Once Amended) The method of claim 1, wherein the peptide is selected from the group consisting of

EKRPPSRSKYL (SEQ ID NO: 29),
EKRPSQRPSYL (SEQ ID NO: 30),
EKRPPSRPSYL (SEQ ID NO: 8),
KRREILSRRPPSYRK (SEQ ID NO: 9),
KHFPQFPSYSAS (SEQ ID NO: 10),
pSPELERLIIQC (SEQ ID NO: 11),
GSPSVRCSpSMpS (SEQ ID NO: 12),
RSRHSpSYPAGT (SEQ ID NO: 13),
LpTPLK (SEQ ID NO: 14),
FpTPLQ (SEQ ID NO: 15),
RKRpTLRRL (SEQ ID NO: 16),
LRRApSLG (SEQ ID NO: 17),
KKLNRTLpSVASL (SEQ ID NO: 18),

A17
con's

RPRAApTF-NH₂ (SEQ ID NO: 19), and

LRRApSLG-NH₂ (SEQ ID NO: 20).

30. (Once Amended) A kinase substrate comprising
a luminophore, and

a peptide sequence selected from the group consisting of

AYTGLSTRNQETYATH-NH₂ (SEQ ID NO: 31),

YYYIE-NH₂ (SEQ ID NO: 32),

GYNELNLGRREEYDVL-NH₂ (SEQ ID NO: 33),

EKRPSRSKYL (SEQ ID NO: 34),

EKRPSQRSYL (SEQ ID NO: 35),

EKRPSRSYL (SEQ ID NO: 36),

KRREILSRRPSYRK (SEQ ID NO: 37),

KHFPQFSYSAS (SEQ ID NO: 38),

SPELERLIIQC (SEQ ID NO: 39),

GSPSVRCSSMS (SEQ ID NO: 40),

RSRHSSYPAGT (SEQ ID NO: 41),

LTPLK (SEQ ID NO: 42),

FTPLQ (SEQ ID NO: 43),

RKRTLRL (SEQ ID NO: 44),

LRRASLG (SEQ ID NO: 45),

KKLNRTL SVASL (SEQ ID NO: 46),

A18

A18
RPRAATF-NH₂ (SEQ ID NO: 47), and
LRRASLG-NH₂ (SEQ ID NO: 48).

32. (Once Amended) The substrate of claim 30, wherein the substrate can be phosphorylated by tyrosine kinase, the peptide having an amino acid sequence selected from the group consisting of

A19
AYTGLSTRNQETYATH-NH₂ (SEQ ID NO: 31),
YYYIE-NH₂ (SEQ ID NO: 32), and
GYNELNLGRREEYDVL-NH₂ (SEQ ID NO: 33).

33. (Once Amended) The substrate of claim 30, wherein the substrate can be phosphorylated by a serine/threonine kinase, the peptide being selected from the group consisting of

A20
EKRPSRSKYL (SEQ ID NO: 34),
EKRPSQRSYL (SEQ ID NO: 35),
EKRPSRSYL (SEQ ID NO: 36),
KRREILSRRPSYRK (SEQ ID NO: 37),
KHFPQFSYSAS (SEQ ID NO: 38),
SPELERLIIQC (SEQ ID NO: 39),
GSPSVRCSSMS (SEQ ID NO: 40),
RSRHSSYPAGT (SEQ ID NO: 41),
LTPLK (SEQ ID NO: 42),

A20
cond

FTPLQ (SEQ ID NO: 43),
RKRTLRL (SEQ ID NO: 44),
LRRASLG (SEQ ID NO: 45),
KKLNRTL SVASL (SEQ ID NO: 46),
RPRAATF-NH₂ (SEQ ID NO: 47), and
LRRASLG-NH₂ (SEQ ID NO: 48).

34. (Once Amended) A composition comprising at least one peptide selected
from the following group

EKRPPSRSKYL (SEQ ID NO: 29),
EKRPSQRPSYL (SEQ ID NO: 30),
EKRPPSRPSYL (SEQ ID NO: 8),
KRREILSRRPPSYRK (SEQ ID NO: 9),
KHFPQFP SYSAS (SEQ ID NO: 10),
pSPELERLIIQC (SEQ ID NO: 11),
GSPSVRCSP SMpS (SEQ ID NO: 12),
RSRHSPSYAGT (SEQ ID NO: 13),
LpTPLK (SEQ ID NO: 14),
FpTPLQ (SEQ ID NO: 15),
RKRpTLRL (SEQ ID NO: 16),
LRRApSLG (SEQ ID NO: 17),
KKLNRTLpSVASL (SEQ ID NO: 18),

A21

A21
con's

RPRAApTF-NH₂ (SEQ ID NO: 19), and

LRRApSLG-NH₂ (SEQ ID NO: 20).

38. (Once Amended) The composition of claim 36, the binding partner binds specifically to at least one peptide selected from the following group

EKRPPSRSKYL (SEQ ID NO: 29),

EKRPSQRpSYL (SEQ ID NO: 30),

EKRPPSRpSYL (SEQ ID NO: 8),

KRREILSRRPpSYRK (SEQ ID NO: 9),

KHFPQFpSYSAS (SEQ ID NO: 10),

pPELERLIIQC (SEQ ID NO: 11),

GSPSVRCSpSMpS (SEQ ID NO: 12),

RSRHSpSYPAGT (SEQ ID NO: 13),

LpTPLK (SEQ ID NO: 14),

FpTPLQ (SEQ ID NO: 15),

RKRpTLRRL (SEQ ID NO: 16),

LRRApSLG (SEQ ID NO: 17),

KKLNRTLpSVASL (SEQ ID NO: 18),

RPRAApTF-NH₂ (SEQ ID NO: 19), and

LRRApSLG-NH₂ (SEQ ID NO: 20).

A22